A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Name: A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Creator: Vivli
Published: 2026-04-29 20:35:18
License: 暂无描述

DataCite Commons2026-04-29 更新2026-05-07 收录

下载链接：

https://search.vivli.org/doiLanding/studies/PR00013052/isLanding

下载链接

链接失效反馈

官方服务：

资源简介：

The purpose of this study was to demonstrate superiority of treatment with avelumab plus best supportive care (BSC) versus physician's choice (chosen from a pre-specified list of therapeutic options) plus BSC.

提供机构：

Vivli

创建时间：

2026-04-29